HSK16149 40mg BID

DRUG4 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

Diabetic Peripheral Neuropathic PainHerpetic NeuralgiaPeripheral Neuropathic PainPostherpetic Neuralgia

Phase 2

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Haisco Pharmaceutical Group Co., Ltd.Diabetic Peripheral Neuropathic Pain

Start: 2020-12-02End: 2022-11-16Target: 687Updated: 2020-12-01

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia

CompletedNCT05763550

Haisco Pharmaceutical Group Co., Ltd.Herpetic Neuralgia

Start: 2023-02-27End: 2023-08-07Updated: 2023-11-08

Phase 3

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

CompletedNCT05140863

Haisco Pharmaceutical Group Co., Ltd.Postherpetic Neuralgia

Start: 2021-11-01End: 2023-01-05Updated: 2023-02-27

To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia

CompletedNCT05890053

Haisco Pharmaceutical Group Co., Ltd.Peripheral Neuropathic Pain

Start: 2022-02-17End: 2023-08-07Updated: 2025-09-04

Related Papers

1432-P: Enhanced Efficacy of Crisugabalin 80 mg/day in Diabetic Peripheral Neuropathic Pain Patients with BMI ≥25 kg/m² or Longer Disease Duration: A Post Hoc Analysis

Diabetes2026-06-05

Rapid Onset of Pain Relief with Crisugabalin in Patients with Diabetic Peripheral Neuropathic Pain: Findings from a Multicenter, Randomized, Double-Blind, Controlled Study

Pain and Therapy2025-05-161 citations

Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia

JAMA Dermatology2024-09-2514 citations

GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

JAMA Network Open2024-08-1913 citations